Results 231 to 240 of about 123,600 (352)

Advances in the study of TIM3 in myelodysplastic syndrome. [PDF]

Front Immunol
Guo X, Yu S, Tao J, Wang Y, Shao Z, Fu R, Li L.   +6 more
europepmc   +1 more source

Single-nucleotide human disease mutation inactivates a blood-regenerative GATA2 enhancer [PDF]

, 2019
Bresnick, Emery H, Cao, Miao, Choi, Kyunghee, Hofmann, Inga, Johnson, Kirby D, Keles, Sunduz, Liu, Peng, Mahta, Charu, Soukup, Alexandra A, Wu, Jun, Zhang, Jing, Zheng, Ye, Zhou, Yun   +12 more
core   +1 more source

Mitochondrial DNA: A Key Alarmin Igniting the Inflammasome Fire in Health and Disease

Immunology, Volume 178, Issue 2, Page 218-230, June 2026.
This review illustrates how mitochondrial DNA, released under cellular stress, acts as a key alarmin that ignites innate immune sensors, particularly inflammasomes and the cGAS‐STING pathway. This paper details how this sustained “inflammasome fire” fuels the progression of diverse inflammatory diseases, including neurodegeneration and metabolic ...
Woo Hyun Park
wiley   +1 more source

A large dataset of bone marrow cells in myelodysplastic syndrome for classification systems. [PDF]

Sci Data
Shen D, Gao X, Tong J, Feng J, Huang Z, Zhang T, Li J, Zhao S, Zhu Y, Xu Y, Yuan S, Jin C, Tong H.   +12 more
europepmc   +1 more source

ERK, p38 AND NF-kappaB SIGNALING IN MONOCYTE DERIVED DENDRITIC CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME [PDF]

, 2014
Ilina Micheva, Liana Gercheva, Panos G. Ziros, Nicholas Zoumbos   +3 more
openalex   +1 more source

Values of Individuals With Rare Genetic Neurodevelopmental Disorders and Their Family/Caregivers in Healthcare: A Scoping Review to Inform Guideline Development

Journal of Intellectual Disability Research, Volume 70, Issue 6, Page 608-652, June 2026.
ABSTRACT Background Healthcare decision‐making for individuals with rare genetic neurodevelopmental disorders (RGNDs) associated with intellectual disabilities (ID) can be complex due to the intersection of lifelong care needs, limited medical expertise and communication barriers.
Mirthe J. Klein Haneveld, Louise Cox, Petri J. C. M. Embregts, Alistair R. Niemeijer, Martina C. Cornel, Charlotte M. W. Gaasterland, Agnies M. van Eeghen   +6 more
wiley   +1 more source

Synergistic effects of luspatercept and cyclosporine A in lower-risk myelodysplastic syndrome with red cell aplasia: Two case insights. [PDF]

Leuk Res Rep
Jo T, Sakai T, Noguchi K, Yamaguchi K, Umemoto K, Abe K, Shigematsu K.   +6 more
europepmc   +1 more source

Clonal hematopoiesis in patients with cancer and cancer survivors: From clonal burden to cardiovascular diseases

Cancer, Volume 132, Issue 10, 15 May 2026.
ABSTRACT Over the past decade, clonal hematopoiesis (CH) has gained substantial attention as a prevalent, age‐associated phenomenon with major implications for hematologic malignancy, cardiovascular disease, and mortality. CH arises from the clonal expansion of hematopoietic stem cells and progenitor cells harboring somatic mutations, most commonly in ...
Christian H. Nenninger, Keith Anderson, Jenaro Espitia‐Corredor, Brittany Echevarria, Vertica Agnihotri, Zhao Wang, Scott R. Goldsmith, June‐Wha Rhee   +7 more
wiley   +1 more source

Treatment of Relapsed/Refractory t(11;14) Multiple Myeloma and High-Risk Myelodysplastic Syndrome With Venetoclax. [PDF]

Case Rep Hematol
Taylor AO, Clune S, Liu J, Gasparetto C, LeBlanc TW.   +4 more
europepmc   +1 more source

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

International Journal of Cancer, Volume 158, Issue 10, Page 2674-2683, 15 May 2026.
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang, Jing‐jing Sun, Zhi Wan, Xiao‐yu Jing, Xia Guo, Ju Gao   +5 more
wiley   +1 more source